Cryo Cell International (CCEL) Operating Income (2010 - 2026)

Cryo Cell International (CCEL) has reported Operating Income for 17 consecutive years, with $1.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Income fell 19.78% year-over-year to $1.2 million; the TTM figure through May 2026 stood at -$103776.0 (down 102.72% YoY), while the FY2025 annual figure was $482394.0, down 86.14% from the prior year.
• Operating Income advanced to $1.2 million in Q2 2026 per CCEL's latest filing, from $765134.0 in the prior quarter.
• Across five years, Operating Income topped out at $1.9 million in Q3 2025 and bottomed at -$16.2 million in Q4 2023.
• Historically, Operating Income has averaged -$130800.7 across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Income jumped 150.14% — and 2023, when it tumbled 4090.56%.
• Cryo Cell International's Operating Income stood at $405360.0 in 2022, then sank by 4090.56% to -$16.2 million in 2023, then surged by 99.24% to -$122347.0 in 2024, then slumped by 3142.24% to -$4.0 million in 2025, then surged by 130.18% to $1.2 million in 2026.
• Business Quant data shows CCEL's Operating Income at $1.2 million in Q2 2026, $765134.0 in Q1 2026, and -$4.0 million in Q4 2025.